Abstract:Purpose: To investigate whether patients who develop aneurysm sac shrinkage following endovascular aneurysm repair (EVAR) have better outcomes than patients with a stable or increased aneurysm sac. Materials and Methods: The Healthcare Databases Advanced Search interface developed by the National Institute for Health and Care Excellence was used to interrogate MEDLINE and EMBASE. Thesaurus headings were adapted accordingly. Case-control studies were identified comparing outcomes in patients demonstrating aneur… Show more
“…This research showed a significantly lower all-cause mortality in patients with a shrinking AAA one-year after EVAR, compared to patients with a stable AAA, confirming data of previous studies [ 7 , 8 , 9 ]. In addition, one death of a patient with a stable AAA was EVAR-related, while none of the patients with AAA shrinkage died from this cause.…”
Section: Discussionsupporting
confidence: 90%
“…A stable or shrinking aneurysm diameter after EVAR has traditionally been considered a treatment success. However, recent studies indicate that patients with AAA shrinkage, at one-year after EVAR, have significantly better long-term outcomes compared to patients with growing AAA, but also to those with stable AAA [ 7 , 8 , 9 , 10 , 11 ]. These outcomes include fewer reinterventions and late complications, less rupture, and a lower all-cause mortality [ 7 , 8 , 9 , 10 , 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…However, recent studies indicate that patients with AAA shrinkage, at one-year after EVAR, have significantly better long-term outcomes compared to patients with growing AAA, but also to those with stable AAA [ 7 , 8 , 9 , 10 , 11 ]. These outcomes include fewer reinterventions and late complications, less rupture, and a lower all-cause mortality [ 7 , 8 , 9 , 10 , 11 ]. These observations were independent of the occurrence of endoleaks and reinterventions performed [ 7 ].…”
Recent studies demonstrate that patients with a shrinking abdominal aortic aneurysm (AAA), one-year after endovascular repair (EVAR), have better long-term outcomes than patients with a stable AAA. It is not known what factors determine whether an AAA will shrink or not. In this study, a range of parameters was investigated to identify their use in differentiating patients that will develop a shrinking AAA from those with a stable AAA one-year after EVAR. Hundred-seventy-four patients (67 shrinking AAA, 107 stable AAA) who underwent elective, infrarenal EVAR were enrolled between 2011–2018. Long-term survival was significantly better in patients with a shrinking AAA, compared to those with a stable AAA (p = 0.038). Larger preoperative maximum AAA diameter was associated with an increased likelihood of developing AAA shrinkage one-year after EVAR—whereas older age and larger preoperative infrarenal β angle were associated with a reduced likelihood of AAA shrinkage. However, this multivariate logistic regression model was only able to correctly identify 66.7% of patients with AAA shrinkage from the total cohort. This is not sufficient for implementation in clinical care, and therefore future research is recommended to dive deeper into AAA anatomy, and explore potential predictors using artificial intelligence and radiomics.
“…This research showed a significantly lower all-cause mortality in patients with a shrinking AAA one-year after EVAR, compared to patients with a stable AAA, confirming data of previous studies [ 7 , 8 , 9 ]. In addition, one death of a patient with a stable AAA was EVAR-related, while none of the patients with AAA shrinkage died from this cause.…”
Section: Discussionsupporting
confidence: 90%
“…A stable or shrinking aneurysm diameter after EVAR has traditionally been considered a treatment success. However, recent studies indicate that patients with AAA shrinkage, at one-year after EVAR, have significantly better long-term outcomes compared to patients with growing AAA, but also to those with stable AAA [ 7 , 8 , 9 , 10 , 11 ]. These outcomes include fewer reinterventions and late complications, less rupture, and a lower all-cause mortality [ 7 , 8 , 9 , 10 , 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…However, recent studies indicate that patients with AAA shrinkage, at one-year after EVAR, have significantly better long-term outcomes compared to patients with growing AAA, but also to those with stable AAA [ 7 , 8 , 9 , 10 , 11 ]. These outcomes include fewer reinterventions and late complications, less rupture, and a lower all-cause mortality [ 7 , 8 , 9 , 10 , 11 ]. These observations were independent of the occurrence of endoleaks and reinterventions performed [ 7 ].…”
Recent studies demonstrate that patients with a shrinking abdominal aortic aneurysm (AAA), one-year after endovascular repair (EVAR), have better long-term outcomes than patients with a stable AAA. It is not known what factors determine whether an AAA will shrink or not. In this study, a range of parameters was investigated to identify their use in differentiating patients that will develop a shrinking AAA from those with a stable AAA one-year after EVAR. Hundred-seventy-four patients (67 shrinking AAA, 107 stable AAA) who underwent elective, infrarenal EVAR were enrolled between 2011–2018. Long-term survival was significantly better in patients with a shrinking AAA, compared to those with a stable AAA (p = 0.038). Larger preoperative maximum AAA diameter was associated with an increased likelihood of developing AAA shrinkage one-year after EVAR—whereas older age and larger preoperative infrarenal β angle were associated with a reduced likelihood of AAA shrinkage. However, this multivariate logistic regression model was only able to correctly identify 66.7% of patients with AAA shrinkage from the total cohort. This is not sufficient for implementation in clinical care, and therefore future research is recommended to dive deeper into AAA anatomy, and explore potential predictors using artificial intelligence and radiomics.
“…We were interested to note this article by Antoniou et al 1 focusing on aneurysm sac shrinkage as a prognosticator for positive outcomes after endovascular aneurysm repair (EVAR), particularly in terms of reduction of rates of reintervention, late aneurysm rupture, other late complications—all considered to be the drawbacks of EVAR—and even death. This would suggest a need to look for particular adjuncts/interventions that might increase the incidence of post-EVAR sac shrinkage, and this aspect has not really been touched upon.…”
“…We propose a surveillance algorithm that takes account of recommendations from the 2 major vascular society clinical practice guidelines 2,3 and considers the most contemporary evidence, applying a color code, that is, red requiring intervention, yellow requiring further investigations or more intensive surveillance, and green raising no concerns (Figure 2). 4 In this algorithm, after the 30-day computed tomography (CT) scan, we propose different paths based on the CT scan findings indicated by the color code, that is, ultrasound (US) surveillance (± abdominal X-ray) at 12 months if there is no endoleak or there is only a type II endoleak, further investigations with contrast-enhanced US or digital subtraction angiography (and subsequent treatment if necessary) if there is an indeterminate endoleak, or immediate treatment if the CT scan shows a type I or III endoleak. Following the 12-month US scan and in the absence of a malignant or indeterminate endoleak, the mode and frequency of surveillance is determined by the sac behavior and the presence of type II endoleak as follows: The proposed algorithm adopts a pragmatic approach to different modes and imaging frequencies.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.